Articles

Targeting the DNA damage response enhances CD70 CAR-T cell therapy for renal carcinoma by activating the cGAS-STING pathway

Chimeric antigen receptor T-cell (CAR-T) therapy has shown tremendous success in eradicating hematologic malignancies. However, this success has not yet been extrapolated to solid tumors due to the limited inf...

Authors: Feng Ji, Fan Zhang, Miaomiao Zhang, Kaili Long, Mingyue Xia, Fei Lu, Enjie Li, Jiannan Chen, Jun Li, Zhengliang Chen, Li Jing, Shaochang Jia, Rong Yang, Zhigang Hu and Zhigang Guo

Prognostic and predictive biomarker developments in multiple myeloma

New approaches to stratify multiple myeloma patients based on prognosis and therapeutic decision-making, or prediction, are needed since patients are currently managed in a similar manner regardless of individ...

Authors: Craig T. Wallington-Beddoe and Rachel L. Mynott

Correction to: Anti-PD-1 antibodies as a salvage therapy for patients with diffuse large B cell lymphoma who progressed/relapsed after CART19/20 therapy

Authors: Chunmeng Wang, Fengxia Shi, Yang Liu, Yajing Zhang, Liang Dong, Xiang Li, Chuan Tong, Yao Wang, Liping Su, Jing Nie and Weidong Han

Homogeneously high expression of CD32b makes it a potential target for CAR-T therapy for chronic lymphocytic leukemia

CD19 chimeric antigen receptor (CAR)-T cells have been used to treat patients with refractory chronic lymphocytic leukemia (CLL). However, approximately 50% of patients do not respond to this therapy. To impro...

Authors: Guoling Wang, Xiaolei Sun, Shiyu Zuo, Chuo Li, Qing Niu, Yonghui Xia, Yuan Meng, Min Liu, Zihao Fang, Xi Yang, Yanyu Jiang, Sheng Wang, Haidong Cui, Huifang Huang, Erlie Jiang, Dongming Zhou…

KAI1(CD82) is a key molecule to control angiogenesis and switch angiogenic milieu to quiescent state

Little is known about endogenous inhibitors of angiogenic growth factors. In this study, we identified a novel endogenous anti-angiogenic factor expressed in pericytes and clarified its underlying mechanism an...

Authors: Jin-Woo Lee, Jin Hur, Yoo-Wook Kwon, Cheong-Whan Chae, Jae-Il Choi, Injoo Hwang, Ji-Yeon Yun, Jin-A Kang, Young-Eun Choi, Young Hyun Kim, Sang Eun Lee, Cheol Lee, Dong Hyun Jo, Heeyoung Seok, Byong Seung Cho, Sung Hee Baek…

Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target

Immune checkpoint therapy has achieved significant efficacy by blocking inhibitory pathways to release the function of T lymphocytes. In the clinic, anti-programmed cell death protein 1/programmed cell death l...

Authors: Wenjing Qian, Mingfang Zhao, Ruoyu Wang and Heming Li

Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers

Our previous work showed that the anti-TGF-β/PD-L1 bispecific antibody YM101 effectively overcame anti-PD-L1 resistance in immune-excluded tumor models. However, in immune-desert models, the efficacy of YM101 ...

Authors: Ming Yi, Mengke Niu, Jing Zhang, Shiyu Li, Shuangli Zhu, Yongxiang Yan, Ning Li, Pengfei Zhou, Qian Chu and Kongming Wu

The consensus from The Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update

The consensus recommendations in 2018 from The Chinese Society of Hematology (CSH) on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation (allo-HSCT) f...

Authors: Xiao-hui Zhang, Jing Chen, Ming-Zhe Han, He Huang, Er-lie Jiang, Ming Jiang, Yong-rong Lai, Dai-hong Liu, Qi-Fa Liu, Ting Liu, Han-yun Ren, Yong-Ping Song, Zi-min Sun, Xiao-wen Tang, Jian-min Wang, De-pei Wu…

Correction to: Low expression of TRAF3IP2-AS1 promotes progression of NONO-TFE3 translocation renal cell carcinoma by stimulating N⁶-methyladenosine of PARP1 mRNA and downregulating PTEN

Authors: Lei Yang, Yi Chen, Ning Liu, QianCheng Shi, Xiaodong Han, Weidong Gan and Dongmei Li

HRAS is a therapeutic target in malignant chemo-resistant adenomyoepithelioma of the breast

Malignant adenomyoepithelioma (AME) of the breast is an exceptionally rare form of breast cancer, with a significant metastatic potential. Chemotherapy has been used in the management of advanced AME patients,...

Authors: Ivan Bièche, Florence Coussy, Rania El-Botty, Sophie Vacher, Sophie Château-Joubert, Ahmed Dahmani, Elodie Montaudon, Cécile Reyes, David Gentien, Fabien Reyal, Francesco Ricci, André Nicolas, Caterina Marchio, Anne Vincent-Salomon, Marick Laé and Elisabetta Marangoni

Modulating tumor infiltrating myeloid cells to enhance bispecific antibody-driven T cell infiltration and anti-tumor response

Tumor microenvironment (TME) is a dynamic cellular milieu to promote tumor angiogenesis, growth, proliferation, and metastasis, while derailing the host anti-tumor response. TME impedes bispecific antibody (Bs...

Authors: Jeong A. Park, Linlin Wang and Nai-Kong V. Cheung

Small extracellular vesicle non-coding RNAs in pancreatic cancer: molecular mechanisms and clinical implications

Pancreatic cancer has the worst prognosis among common tumors which is attributed to its aggressive phenotype, diagnosis at advanced, inoperable stages, and resistance to systemic therapy. Non-coding RNAs (ncR...

Authors: Moritz Reese and Sameer A. Dhayat

Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma

In the absence of randomized studies directly comparing chimeric antigen receptor T cell therapies, this study used matching-adjusted indirect comparisons (MAIC) to evaluate the comparative efficacy and safety...

Authors: David G. Maloney, John Kuruvilla, Fei Fei Liu, Ana Kostic, Yeonhee Kim, Ashley Bonner, Yixie Zhang, Christopher P. Fox and Guillaume Cartron

Intracellular delivery of anti-BCR/ABL antibody by PLGA nanoparticles suppresses the oncogenesis of chronic myeloid leukemia cells

The pathogenesis of chronic myeloid leukemia (CML) is the formation of the BCR/ABL protein, which is encoded by the bcr/abl fusion gene, possessing abnormal tyrosine kinase activity. Despite the wide applicati...

Authors: Guoyun Jiang, Zhenglan Huang, Ying Yuan, Kun Tao and Wenli Feng

Protein degradation technology: a strategic paradigm shift in drug discovery

Targeting pathogenic proteins with small-molecule inhibitors (SMIs) has become a widely used strategy for treating malignant tumors. However, most intracellular proteins have been proven to be undruggable due ...

Authors: Haobin Li, Jinyun Dong, Maohua Cai, Zhiyuan Xu, Xiang-Dong Cheng and Jiang-Jiang Qin

Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia

Quantification of measurable residual disease (MRD) provides critical prognostic information in acute myeloid leukemia (AML). A variety of platforms exist for MRD detection, varying in their sensitivity and ap...

Authors: Marisa J. L. Aitken, Farhad Ravandi, Keyur P. Patel and Nicholas J. Short

Therapeutic roles of mesenchymal stem cell-derived extracellular vesicles in cancer

Extracellular vesicles (EVs) are cell-derived membrane structures enclosing proteins, lipids, RNAs, metabolites, growth factors, and cytokines. EVs have emerged as essential intercellular communication regulat...

Authors: Zhijie Weng, Bowen Zhang, Chenzhou Wu, Fanyuan Yu, Bo Han, Bo Li and Longjiang Li

Correction to: MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies

Authors: Seyed Esmaeil Ahmadi, Samira Rahimi, Bahman Zarandi, Rouzbeh Chegeni and Majid Safa

Circular RNAs: characteristics, biogenesis, mechanisms and functions in liver cancer

Hepatocellular carcinoma (HCC) is one of the most common malignancies globally. Despite aggressive and multimodal treatment regimens, the overall survival of HCC patients remains poor.

Authors: Hao Shen, Boqiang Liu, Junjie Xu, Bin Zhang, Yifan Wang, Liang Shi and Xiujun Cai

Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial

Most older patients with acute myeloid leukemia (AML) who attain morphologic remission with intensive chemotherapy (IC) will eventually relapse and post-relapse prognosis is dismal. In the pivotal QUAZAR AML-0...

Authors: Farhad Ravandi, Gail J. Roboz, Andrew H. Wei, Hartmut Döhner, Christopher Pocock, Dominik Selleslag, Pau Montesinos, Hamid Sayar, Maurizio Musso, Angela Figuera-Alvarez, Hana Safah, William Tse, Sang Kyun Sohn, Devendra Hiwase, Timothy Chevassut, Francesca Pierdomenico…

The antibody drug conjugate VLS-101 targeting ROR1 is effective in CAR T-resistant mantle cell lymphoma

Mantle cell lymphoma (MCL) is a rare, aggressive and incurable subtype of non-Hodgkin’s B-cell lymphoma. The principal barrier is frequent clinical relapse to multiple lines of therapies, including new FDA-app...

Authors: Vivian Changying Jiang, Yang Liu, Alexa Jordan, Joseph McIntosh, Yijing Li, Yuxuan Che, Katti A. Jessen, Brian J. Lannutti and Michael Wang

Clinical features and outcomes of 1845 patients with follicular lymphoma: a real-world multicenter experience in China

Clinical features and outcomes of FL patients in Chinese population are limited, thus promoting us to perform this analysis on a large cohort of 1845 patients with FL enrolled from nine medical centers nationw...

Authors: Jie Zha, Liyuan Fan, Shuhua Yi, Haifeng Yu, Zhong Zheng, Wei Xu, Manman Deng, Zhijuan Lin, Zhifeng Li, Lingyan Ping, Xiaohua He, Feili Chen, Ying Xie, Biyun Chen, Huilai Zhang, Li Wang…

Phase 1 clinical trial of the PI3Kδ inhibitor YY-20394 in patients with B-cell hematological malignancies

YY-20394, an oral phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor, was investigated in a first-in-human study of patients with relapsed or refractory B-cell malignancies. During dose escalation, 25 patie...

Authors: Bo Jiang, Junyuan Qi, Yuqin Song, Zengjun Li, Meifeng Tu, Lingyan Ping, Zongliang Liu, Hanying Bao, Zusheng Xu and Lugui Qiu

Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer

METex14 skipping mutations occur in about 3–4% of lung adenocarcinoma patients and 1–2% of patients with other lung cancer histology. The MET receptor tyrosine kinase and its ligand hepatocyte growth factor (H...

Authors: Leylah M. Drusbosky, Richa Dawar, Estelamari Rodriguez and Chukwuemeka V. Ikpeazu

Targeting Akt in cancer for precision therapy

Biomarkers-guided precision therapeutics has revolutionized the clinical development and administration of molecular-targeted anticancer agents. Tailored precision cancer therapy exhibits better response rate ...

Authors: Hui Hua, Hongying Zhang, Jingzhu Chen, Jiao Wang, Jieya Liu and Yangfu Jiang

Phase 1 study of M2698, a p70S6K/AKT dual inhibitor, in patients with advanced cancer

The PI3K/AKT/mTOR (PAM) pathway is a key regulator of tumor therapy resistance. We investigated M2698, an oral p70S6K/AKT dual inhibitor, in patients with advanced cancer who failed standard therapies.

Authors: Apostolia-Maria Tsimberidou, Jamie V. Shaw, Dejan Juric, Claire Verschraegen, Amy M. Weise, John Sarantopoulos, Gilberto Lopes, John Nemunaitis, Monica Mita, Haeseong Park, Barbara Ellers-Lenz, Hui Tian, Wenyuan Xiong, Remigiusz Kaleta and Razelle Kurzrock

Making clinical decisions based on measurable residual disease improves the outcome in multiple myeloma

The assessment of measurable residual disease (MRD) in bone marrow has proven of prognostic relevance in patients with multiple myeloma (MM). Nevertheless, and unlike other hematologic malignancies, the use of...

Authors: Joaquin Martinez-Lopez, Rafael Alonso, Sandy W. Wong, Rafael Rios, Nina Shah, Yanira Ruiz-Heredia, Jose Maria Sanchez-Pina, Ricardo Sanchez, Natasha Bahri, Irene Zamanillo, Maria Poza, Natalia Buenache, Cristina Encinas, Luis Juarez, Fatima Miras, Luis Collado…

Targeting the tumor microenvironment in B-cell lymphoma: challenges and opportunities

B-cell lymphoma is a group of hematological malignancies with high clinical and biological heterogeneity. The pathogenesis of B-cell lymphoma involves a complex interaction between tumor cells and the tumor mi...

Authors: Yingyue Liu, Xiangxiang Zhou and Xin Wang

Anticancer bispecific antibody R&D advances: a study focusing on research trend worldwide and in China

The bispecific antibody (bsAbs) research around the world has undergone great changes. We analyzed the global trend of bsAbs research and compared the differences in clinical research of bsAbs between China an...

Authors: Zhonghan Zhang, Fan Luo, Jiaxin Cao, Feiteng Lu, Yang Zhang, Yuxiang Ma, Kangmei Zeng, Li Zhang and Hongyun Zhao

SELP Asp603Asn and severe thrombosis in COVID-19 males

Thromboembolism is a frequent cause of severity and mortality in COVID-19. However, the etiology of this phenomenon is not well understood. A cohort of 1186 subjects, from the GEN-COVID consortium, infected by...

Authors: Chiara Fallerini, Sergio Daga, Elisa Benetti, Nicola Picchiotti, Kristina Zguro, Francesca Catapano, Virginia Baroni, Simone Lanini, Alessandro Bucalossi, Giuseppe Marotta, Francesca Colombo, Margherita Baldassarri, Francesca Fava, Giada Beligni, Laura Di Sarno, Diana Alaverdian…

Treatment-induced arteriolar revascularization and miR-126 enhancement in bone marrow niche protect leukemic stem cells in AML

During acute myeloid leukemia (AML) growth, the bone marrow (BM) niche acquires significant vascular changes that can be offset by therapeutic blast cytoreduction. The molecular mechanisms of this vascular pla...

Authors: Bin Zhang, Le Xuan Truong Nguyen, Dandan Zhao, David E. Frankhouser, Huafeng Wang, Dinh Hoa Hoang, Junjing Qiao, Christina Abundis, Matthew Brehove, Yu-Lin Su, Yuxin Feng, Anthony Stein, Lucy Ghoda, Adrianne Dorrance, Danilo Perrotti, Zhen Chen…

MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies

MYC oncogene is a transcription factor with a wide array of functions affecting cellular activities such as cell cycle, apoptosis, DNA damage response, and hematopoiesis. Due to the multi-functionality of MYC,...

Authors: Seyed Esmaeil Ahmadi, Samira Rahimi, Bahman Zarandi, Rouzbeh Chegeni and Majid Safa

High-resolution Hi-C maps highlight multiscale 3D epigenome reprogramming during pancreatic cancer metastasis

Pancreatic cancer’s poor prognosis is caused by distal metastasis, which is associated with epigenetic changes. However, the role of the 3D epigenome in pancreatic cancer biology, especially its metastasis, re...

Authors: Bo Ren, Jinshou Yang, Chengcheng Wang, Gang Yang, Huanyu Wang, Yuan Chen, Ruiyuan Xu, Xuning Fan, Lei You, Taiping Zhang and Yupei Zhao

Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia

In a population of 42 Philadelphia negative myeloproliferative neoplasm patients, all on systemic active treatment, the likelihood of responding to anti-SARS-CoV-2 BNT162b2 vaccine at 2 weeks after the second ...

Authors: Fulvia Pimpinelli, Francesco Marchesi, Giulia Piaggio, Diana Giannarelli, Elena Papa, Paolo Falcucci, Antonio Spadea, Martina Pontone, Simona Di Martino, Valentina Laquintana, Antonia La Malfa, Enea Gino Di Domenico, Ornella Di Bella, Gianluca Falzone, Fabrizio Ensoli, Branka Vujovic…

IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin

Although chimeric antigen receptor (CAR)-engineered T cells have shown great success in the treatment of B cell malignancies, this strategy has limited efficacy in patients with solid tumors. In mouse CAR-T ce...

Authors: Nengzhi Pang, Jingxuan Shi, Le Qin, Aiming Chen, Yuou Tang, Hainan Yang, Yufeng Huang, Qingde Wu, Xufeng Li, Bingjia He, Tianheng Li, Baoxia Liang, Jinglin Zhang, Bihui Cao, Manting Liu, Yunfei Feng…

N6-methyladenosine methyltransferases: functions, regulation, and clinical potential

N6-methyladenosine (m6A) has emerged as an abundant modification throughout the transcriptome with widespread functions in protein-coding and noncoding RNAs. It affects the fates of modified RNAs, including th...

Authors: Wei Huang, Tian-Qi Chen, Ke Fang, Zhan-Cheng Zeng, Hua Ye and Yue-Qin Chen

Emerging strategies to target RAS signaling in human cancer therapy

RAS mutations (HRAS, NRAS, and KRAS) are among the most common oncogenes, and around 19% of patients with cancer harbor RAS mutations. Cells harboring RAS mutations tend to undergo malignant transformation and ex...

Authors: Kun Chen, Yalei Zhang, Ling Qian and Peng Wang

Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond

The pace of innovation of multiple myeloma therapy in recent years is remarkable with the advent of monoclonal antibodies and the approval of novel agents with new mechanisms of action. Emerging therapies are ...

Authors: Christopher T. Su and J. Christine Ye

Metabolic landscapes in sarcomas

Metabolic rewiring offers novel therapeutic opportunities in cancer. Until recently, there was scant information regarding soft tissue sarcomas, due to their heterogeneous tissue origin, histological definitio...

Authors: Richard Miallot, Franck Galland, Virginie Millet, Jean-Yves Blay and Philippe Naquet

Dasatinib enhances anti-leukemia efficacy of chimeric antigen receptor T cells by inhibiting cell differentiation and exhaustion

Relapses of CD19-expressing leukemia in patients who achieved initial remission after CART cell treatment have been reported to correlate with poor CART cells persistence. Sustained tonic signaling or strong a...

Authors: Hao Zhang, Yongxian Hu, Mi Shao, Xinyi Teng, Penglei Jiang, Xiujian Wang, Hui Wang, Jiazhen Cui, Jian Yu, Zuyu Liang, Lijuan Ding, Yingli Han, Jieping Wei, Yulin Xu, Xiaoqing Li, Wei Shan…

LCAT3, a novel m6A-regulated long non-coding RNA, plays an oncogenic role in lung cancer via binding with FUBP1 to activate c-MYC

Long non-coding RNAs (lncRNAs) are important epigenetic regulators, which play critical roles in diverse physiological and pathological processes. However, the regulatory mechanism of lncRNAs in lung carcinoge...

Authors: Xinyi Qian, Juze Yang, Qiongzi Qiu, Xufan Li, Chengxi Jiang, Jia Li, Liangliang Dong, Kejing Ying, Bingjian Lu, Enguo Chen, Pengyuan Liu and Yan Lu

Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study

Patients with RR DLBCL who have received ≥ 2 lines of therapy have limited treatment options and an expected overall survival (OS) of < 6 months. The SADAL study evaluated single-agent oral selinexor in patien...

Authors: Marie Maerevoet, Josee M. Zijlstra, George Follows, Rene-Olivier Casasnovas, J. S. P. Vermaat, Nagesh Kalakonda, Andre Goy, Sylvain Choquet, Eric Van Den Neste, Brian Hill, Catherine Thieblemont, Federica Cavallo, Fatima De la Cruz, John Kuruvilla, Nada Hamad, Ulrich Jaeger…

Quality-adjusted Time Without Symptoms of disease or Toxicity (Q-TWiST) analysis of CPX-351 versus 7 + 3 in older adults with newly diagnosed high-risk/secondary AML

CPX-351 (United States: Vyxeos^®; Europe: Vyxeos^® Liposomal), a dual-drug liposomal encapsulation of daunorubicin and cytarabine in a synergistic 1:5 molar ratio, is approved by the US FDA and the EMA for the trea...

Authors: Jorge E. Cortes, Tara L. Lin, Geoffrey L. Uy, Robert J. Ryan, Stefan Faderl and Jeffrey E. Lancet

YTHDF2 facilitates UBXN1 mRNA decay by recognizing METTL3-mediated m⁶A modification to activate NF-κB and promote the malignant progression of glioma

The prognosis for diffuse gliomas is very poor and the mechanism underlying their malignant progression remains unclear. Here, we aimed to elucidate the role and mechanism of the RNA N6,2′-O-dimethyladenosine (m⁶

Authors: Rui-Chao Chai, Yu-Zhou Chang, Xin Chang, Bo Pang, Song Yuan An, Ke-Nan Zhang, Yuan-Hao Chang, Tao Jiang and Yong-Zhi Wang

Targeted therapy in advanced non-small cell lung cancer: current advances and future trends

Lung cancer remains the leading cause of cancer-related mortality in both men and women in the US and worldwide. Non-small cell lung cancer is the most common variety accounting for 84% of the cases. For a sub...

Authors: Umair Majeed, Rami Manochakian, Yujie Zhao and Yanyan Lou

Precision oncology in AML: validation of the prognostic value of the knowledge bank approach and suggestions for improvement

Recently, a novel knowledge bank (KB) approach to predict outcomes of individual patients with acute myeloid leukemia (AML) was developed using unbiased machine learning. To validate its prognostic value, we a...

Authors: Marius Bill, Krzysztof Mrózek, Brian Giacopelli, Jessica Kohlschmidt, Deedra Nicolet, Dimitrios Papaioannou, Ann-Kathrin Eisfeld, Jonathan E. Kolitz, Bayard L. Powell, Andrew J. Carroll, Richard M. Stone, Ramiro Garzon, John C. Byrd, Clara D. Bloomfield and Christopher C. Oakes

Anti-PD-1 antibodies as a salvage therapy for patients with diffuse large B cell lymphoma who progressed/relapsed after CART19/20 therapy

CD19-directed chimeric antigen receptor T cell (CART19) therapy is efficient and approved for relapsed/refractory diffuse large B cell lymphoma (DLBCL). To increase durable antitumor response, we previously de...

Authors: Chunmeng Wang, Fengxia Shi, Yang Liu, Yajing Zhang, Liang Dong, Xiang Li, Chuan Tong, Yao Wang, Liping Su, Jing Nie and Weidong Han

A dual inhibitor overcomes drug-resistant FLT3-ITD acute myeloid leukemia

FLT3 mutations are the most frequently identified genetic alterations in acute myeloid leukemia (AML) and are associated with poor prognosis. Multiple FLT3 inhibitors are in various stages of clinical evaluati...

Authors: Peihong Wang, Xinhua Xiao, Yuyin Zhang, Baoyuan Zhang, Donghe Li, Mingzhu Liu, Xi Xie, Chenxuan Liu, Ping Liu and Ruibao Ren

Evolving therapeutic landscape in follicular lymphoma: a look at emerging and investigational therapies

Follicular Lymphoma (FL) is the most common subtype of indolent B cell non-Hodgkin lymphoma. The clinical course can be very heterogeneous with some patients being safely observed over many years without ever ...

Authors: Walter Hanel and Narendranath Epperla

Molecular pathogenesis of the myeloproliferative neoplasms

The Philadelphia negative myeloproliferative neoplasms (MPN) compromise a heterogeneous group of clonal myeloid stem cell disorders comprising polycythaemia vera, essential thrombocythaemia and primary myelofi...

Authors: Graeme Greenfield, Mary Frances McMullin and Ken Mills